Blurbs

SVB Securities Sticks to Their Buy Rating for Immatics (IMTX)

In a report released on November 17, Jonathan Chang from SVB Securities reiterated a Buy rating on Immatics (IMTXResearch Report), with a price target of $17.00. The company’s shares closed last Friday at $10.55.

Chang covers the Healthcare sector, focusing on stocks such as Bicycle Therapeutics, Immatics, and ImmunoGen. According to TipRanks, Chang has an average return of -13.0% and a 28.57% success rate on recommended stocks.

Immatics has an analyst consensus of Moderate Buy, with a price target consensus of $22.50, implying an 113.27% upside from current levels. In a report released on November 17, Chardan Capital also reiterated a Buy rating on the stock with a $28.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Based on Immatics’ latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $17.22 million and a GAAP net loss of $13.98 million. In comparison, last year the company earned a revenue of $5.19 million and had a GAAP net loss of $26.53 million

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Immatics NV is engaged in discovery of true targets for cancer immunotherapies with the development of the right T cell receptors. The company’s pipeline consists of two lead product classes, engineered Adoptive Cell Therapies (ACTengine) and antibody-like TCR Bispecifics (TCER). Each therapeutic modality has distinct attributes to produce the desired therapeutic effect for patients at different disease stages and with different types of tumors focusing on particularly hard-to-treat solid cancers.

Read More on IMTX:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More